【摘要】 目的观察预混门冬氨酸胰岛素30/70(降血糖药)对2型糖尿病的疗效与安全性。方法选初诊或单用口服降糖药物治疗血糖控制不佳的2型糖尿病患者116例,随机分为2组:预混门冬氨酸胰岛素30/70(治疗组)60例,精蛋白生物合成人胰岛素30/70(对照组)56例,观察各时段血糖变化。结果2组在强化血糖达标后,早、中、晚餐后30,60,120min血糖比较均有显著性差异(P<0.0001~0.020);且治疗组HbA1C下降更显著(P<0.05)。血糖控制后24h的胰岛素用量,治疗组较对照组减少约20%(P<0.05)。结论预混门冬氨酸胰岛素30/70降餐后血糖和HbA1C明显优于精蛋白生物合成人胰岛素30/70。更多还原

【Abstract】 Objective To investigate the efficacy and safety of insulin aspart 30/70 in the treatment of type 2 diabetes mellitus(T2DM). Methods Choose 116 cases T2DM which are newly diagnosed or poorly controlled with oral antidiabetic drugs.They are randomly divided into (insulin aspart 30/70) trial group 60 cases and (biphasic human insulin 30/70) control group 56 cases.To observe the changes of blood glucose levels in various periods.Results when the blood levels reach the controlling values after intensive treatment. There are marked difference after the three meals 30,60 and 120 minutes (P<0.0001~0.020).And the decrease of HbA1c in trial group is obvious (P<0.05). The 24 hour insulin amount after reaching good control of blood levels decrease about 20 in trial group than in the control group (P<0.05).Conclusion Insulin aspart 30/70 is better than the biphasic human insulin 30/70 in lowering postprandial blood glucose and HbA1c .更多还原